Evidence map›Paper›PMID 42187576›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Global Disparities and Trends in Radiotherapy for Early-Stage Glottic Cancer.

Issa Mohamad, Shatha Abu Taha, Ahmad Bushehri, Bassem Youssef, Enis Ozyar, Ibrahim Alotain, Ibrahim Abu-Gheida, Mohammed Aldehaim, Carlton Johnny, Layth Mula-Hussain and 15 more

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Issa MohamadDepartment of Radiation Oncology, King Hussein Cancer Center, Amman 11941, Jordan.ORCID 0000-0003-0153-9131
Shatha Abu TahaDepartment of Radiation Oncology, King Hussein Cancer Center, Amman 11941, Jordan.
Ahmad BushehriDepartment of Radiation Oncology, Kuwait Cancer Control Center, Kuwait City 7065, Kuwait.
Bassem YoussefDepartment of Radiation Oncology, American University of Beirut Medical Centre, Beirut 11-0236, Lebanon.ORCID 0000-0003-3960-8155
Enis OzyarDepartment of Radiation Oncology, Acibadem MAA University School of Medicine, Istanbul 34457, Turkey.ORCID 0000-0002-9497-7976
Ibrahim AlotainDepartment of Radiation Oncology, King Fahad Specialist, Dammam 31444, Saudi Arabia.
Ibrahim Abu-GheidaDepartment of Radiation Oncology, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates.
Mohammed AldehaimDepartment of Radiation Oncology, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.ORCID 0009-0004-6470-3589
Carlton JohnnyDepartment of Radiation Oncology, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
Layth Mula-HussainDivision of Radiation Oncology, Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.ORCID 0000-0003-0218-7270
Majed AlghamdiRadiation Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, Jeddah 11426, Saudi Arabia.
Mohamed ShelanDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-6477-6655
Mohammed Al DohanDepartment of Radiation Oncology, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Nadeem PervezDepartment of Radiation Oncology, Shifa Tameer- e-Miller University, Islamabad 44000, Pakistan.ORCID 0000-0003-3821-4357
Olgun ElicinDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-6996-0646
Saad AlrashidiDepartment of Radiation Oncology, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Wael El-SheshtawyDepartment of Clinical Oncology, Al-Azhar University, Cairo 11827, Egypt.
Shoukri TemrazClinical Oncology Department, Mansoura University Hospital, Mansour 35516, Egypt.
Zineb DahbiDepartment of Radiation Oncology, Mohammed University VI of Health, and Sciences, Casablanca 27182, Morocco.
Ahmed AbbasiDepartment of Radiation Oncology, Aga Khan University Hospital, Stadium Road, Karachi 74800, Pakistan.
Abdulrahman SumaidaRadiation Oncology Department, Tawam Hospital, Al Ain 15258, United Arab Emirates.
Hikmat Abdel-RazeqDepartment of Internal Medicine, King Hussein Cancer Center, Amman 11941, Jordan.ORCID 0000-0003-2833-6051
Khawla AmmarOffice of Scientific Affairs and Research, Survey Unit, King Hussein Cancer Center, Amman 11941, Jordan.ORCID 0000-0003-0616-3110
Akram Al-IbraheemDepartment of Nuclear Medicine, King Hussein Cancer Center, Amman 11941, Jordan.ORCID 0000-0002-0978-4716
Ali HosniRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated global radiotherapy practices in the management of early-stage (AJCC/UICC 8th edition stages I-II) glottic cancer (ESGC). A cross-sectional online survey was conducted in March 2025 across centers worldwide. Data was collected on clinical practices, including staging, CT simulation, target volumes delineation, organs-at-risk contouring, radiotherapy techniques, dose and fractionation schedules, treatment delivery techniques, and image guidance practices. A total of 181 responses were received, primarily from Asia (41.4%) and Europe (24.3%). Most respondents were from non-academic public centers (44.2%), with multidisciplinary team involvement reported by 84.5%. Head and neck CT scan was the most used staging modality (80.1%). Intensity-Modulated Radiation Therapy was the most common planning technique (82.9%). Hypofractionated radiotherapy schedules predominated for T1 (84%) and T2 (72.4%) disease. T1a was typically treated with whole-larynx target volume (72.4%). Use of ipsilateral involved vocal cord irradiation varied by geographical region (

Indexed as

GlottisLaryngeal NeoplasmsCross-Sectional StudiesHumansNeoplasm Stagingaltered fractionationearly-stage laryngeal cancerhypofractionationipsilateral vocal cord irradiationpractice patternswhole laryngeal radiotherapy

Identifiers

PMID42187576
PMCPMC13206154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.